Shares of Molina Healthcare, Inc. MOH are now fairly valued after eclipsing the $90 level, according to JPMorgan.
The Analyst
JPMorgan's Gary Taylor downgraded Molina from Overweight to Neutral with a price target lifted from $91 to $106.
The Thesis
Molina is a "pure play" stock for investors looking for exposure to low-income health insurance companies, Taylor said in the downgrade note.
While it remains well-positioned to benefit from Medicaid programs and subsidized coverage offered through federal and state health care exchanges, the bullish case for the stock can no longer be made after trading above the analyst's $91 price target, he said.
Molina's stock is now trading at a more fair valuation of 15 times Taylor's 2020 earnings per share estimate on a fully normalized pretax margin, the analyst said. The valuation implies the company will see a complete recovery in margins and fall in line with its peers, he said.
Any incremental upside beyond the analyst's price target would have to come from a "much higher view" of sustainable margins than Medicaid plans have ever achieved or from new revenue opportunities, Taylor said.
Price Action
Molina shares were trading down 1.24 percent at $98.17 at the time of publication Wednesday.
Related Links:
Eli Lilly CEO Calls For Uniform Prices, Better Use Of Technology In Health Care
Continued Strength In Medicaid Bodes Well For WellCare, Argus Says
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.